Summary & Overview
HCPCS M1205: Itch Severity Improvement Assessment
HCPCS Level II code M1205 denotes an outcome-based assessment: a reduction of 3 or more points on an itch severity score between the index assessment and a follow-up visit. As an outcome measure, M1205 signals clinically meaningful symptom improvement and supports documentation of treatment effectiveness for dermatologic, allergy, and related ambulatory care services. Nationally, measures of symptom change like this inform quality reporting, care management, and value-based payment arrangements.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on where this code applies clinically, the typical ambulatory sites of service, and how such an outcome measure is used in practice. The publication summarizes common modifier usage and payer considerations where available, highlights benchmarking approaches for outcome measures, and outlines implications for documentation and coding workflows.
This overview is intended for clinicians, billing professionals, and policy analysts seeking a concise reference to the clinical meaning and operational role of M1205 in ambulatory care quality measurement.
Billing Code Overview
HCPCS Level II code M1205 indicates an itch severity assessment score reduction of 3 or more points from the initial (index) assessment to the follow-up visit. This measure captures a clinically meaningful improvement in patient-reported itch severity between visits.
Service type: Assessment / Outcome Measurement
Typical site of service: Outpatient clinic, dermatology or allergy/immunology practice, wound care clinic, or other ambulatory care settings where symptom severity is assessed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old female with chronic plaque psoriasis presents to a dermatology clinic for routine follow-up after initiation of a new systemic therapy. At the index visit the clinician documented an itch severity score (using a validated numeric rating scale 0–10) of 7. At the follow-up visit 8 weeks later the patient reports an itch score of 3, representing a reduction of 4 points from the index assessment. The clinician repeats the itch severity assessment, documents the index and current scores, and records the change of 3 or more points required by billing guideline M1205. The clinical workflow includes: initial assessment and documentation of the baseline itch score at the index visit; initiation or adjustment of therapy; scheduled follow-up visit with repeat itch score; comparison and documentation that the follow-up score decreased by at least three points; submission of the HCPCS Level II code M1205 on the claim with appropriate visit CPT code and applicable modifier(s) as indicated by payer rules. Typical site of service is an outpatient dermatology clinic or ambulatory infusion/infusion suite when medication adjustments occur. Typical patient scenarios include inflammatory skin disease with pruritus (psoriasis, atopic dermatitis, prurigo nodularis), chronic kidney disease–associated pruritus managed in nephrology clinics, or pruritus associated with cholestatic liver disease evaluated in hepatology clinics.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|